



**RESEARCH ARTICLE**

# Guide to Prevention of Central Line Associated Bloodstream Infections & Health Care-Associated Infections for Strategically Targeting Interventions

**<sup>1</sup>Moi Lin Ling\*, Anucha Apisarntharak, Namita Jaggi, Glenys Harrington, Keita Morikane, Le Thi Anh Thu, Patricia Ching, Victoria Villanueva, Zhiyong Zong, Jae Sim Jeong & Chun-Ming Lee**

Received Date:  
24/02/2022  
Revised Date:  
16/03/2022  
Accepted Date:  
28/03/2022  
Published Date  
10/04/2022

<sup>1</sup>Moi Lin Ling\*, Singapore General Hospital, Outram Road, Singapore, 169608, Singapore  
Anucha Apisarntharak, Thammasat University Hospital, Bangkok, Thailand  
Namita Jaggi, Artemis Hospital, New Delhi, India  
Glenys Harrington, Infection Control Consultancy (ICC), Melbourne, Australia  
Keita Morikane, Yamagata University Hospital, Yamagata, Japan  
Le Thi Anh Thu, Cho Ray Hospital, Ho Chi Minh, Vietnam  
Patricia Ching, Hong Kong Baptist Hospital, Kowloon, Hong Kong  
Victoria Villanueva, Chong Hua Hospital, Cebu City, Philippines  
Zhiyong Zong, West China Hospital of Sichuan University, Chengdu, China  
Jae Sim Jeong, Asan Medical Center, Seoul, Korea  
Chun-Ming Lee, MacKay Memorial Hospital, Taipei City, Taiwan

**Corresponding Author:**

*Moi Lin Ling\*, Singapore General Hospital, Outram Road, Singapore, 169608, Singapore*

**Citation:**

*Moi Lin Ling\*, Anucha Apisarntharak, Namita Jaggi, Glenys Harrington, Keita Morikane, Le Thi Anh Thu, Patricia Ching, Victoria Villanueva, Zhiyong Zong, Jae Sim Jeong & Chun-Ming Lee (2022) Guide for Prevention of Central Line Associated Bloodstream Infections & Health Care-Associated Infections for Strategically Targeting Interventions. World J Case Rep Clin Img. 2022 Feb - Apr; 01(1):1-8.*

**Copyrights**

© 2022, This article is licensed under the Creative Commons Attribution-Non Commercial-4.0-International-License- (CCBY-NC) (<https://worldjournalofcasereports.org/blogpage/copyright-policy>). Usage and distribution for commercial purposes require written permission.

**Abstract**

This document is an administrative summary of the APSIC Guide for Prevention of Central Line Associated Bloodstream Infections (CLABSI). It describes crucial substantiation- grounded care factors of the Central Line Insertion and Conservation Packets and its perpetration using the quality enhancement methodology, videlicet the Plan-Do-Study-Act (PDSA) methodology involving multidisciplinary process and stakeholders. Monitoring of enhancement over time with timely feedback to stakeholders is a crucial element to insure the success of enforcing stylish practices. A surveillance program is recommended to cover issues and adherence to substantiation- grounded central line insertion and conservation practices (compliance rate) and identify quality enhancement openings and strategically targeting interventions for the reduction of CLABSI.

**Keywords:** Central line associated bloodstream infections, CLABSI, Insertion bundle, Maintenance bundle, Quality improvement

## Introduction

Central Line-Associated Blood Stream Infections (CLABSI) are dangerous infections that increase mortality, prolong hospital stay, and increase treatment costs. Practices that prevent CLABSI include aseptic insertion techniques and maintenance of the central line (Figure 1).




Figure 1: Central Line Associated Blood Stream Infections

Central lines are intravascular catheters similar to an intravenous line that terminate at or near the heart or the great vessels. These may be used for infusions, withdrawal of blood, or hemodynamic monitoring.

Great vessels include the following:

- Aorta
- Pulmonary artery
- Superior vena cava
- Inferior vena cava
- Brachiocephalic veins
- Internal jugular veins
- Subclavian veins
- External iliac veins
- Common iliac veins
- Femoral veins
- Umbilical artery/vein in neonates

Arterial catheters, arteriovenous fistulas and grafts, extracorporeal membrane, hemodialysis catheters, intra-aortic balloon devices, and ventricular assist devices are not central lines.

Central lines may be:

- **Permanent:** tunneled or implantable catheter
- **Temporary:** non-tunneled, non-implanted catheter
- **Umbilical:** used in neonates

## Definition

**CLABSI** is a laboratory-confirmed, primary bloodstream infection in a patient with an eligible central line.

**Laboratory-confirmed bloodstream infection** is defined:

- When a recognized pathogen, which is not a common commensal, is isolated from one or more blood specimens and presence of the pathogen is not related to infections in any other site.
- When the isolate is commensal, it must be present in two or more blood specimens, and the patient must show signs of infection like fever, chills, or hypotension. The presence of the organism is not related to infections in any other site (Figure 2).




Figure 2: laboratory confirmed blood stream infection

## Microbiology

The most commonly reported organisms associated with CLABSI include the following (Figure 3):

- Coagulase-negative staphylococci
- *Staphylococcus aureus*
- *Enterococcus* species
- *Klebsiella* spp.
- *E. coli*
- *Pseudomonas* spp.
- *Acinetobacter* spp.
- *Candida* species

Antimicrobial resistance is a common problem among most isolates. Methicillin-resistant *Staphylococcus aureus*, ESBL producing Enterobacteriaceae, ceftazidime and carbapenem-




Figure 3: microbiology of CLABSI

resistant *pseudomonas* species, and fluconazole-resistant *Candida* spp. are also being commonly isolated.

**Pathogenesis**

A CLABSI may occur by any of the following mechanisms (Figure 4).




Figure 4: Pathogenesis of CLABSI

Commensal bacteria on the skin's surface may migrate along the catheter insertion tract and colonize the tip. This is the most common route of contamination. The catheter hub or the catheter may be contaminated by direct contact with hands. Organisms

may be carried through the bloodstream from another site of infection and seed the catheter. Infusion of a contaminated fluid may lead to a bloodstream infection.

Virulence of the infecting organisms, host defense mechanisms, and the catheter material used determine the severity of the infection. These factors may increase the adherence of the infecting organism to the catheter and promote colonization. Non-tunneled central lines account for a higher number of infections than the tunneled variety.

**Factors that increase the risk of CLABSI (Table 1).**

Clinical manifestations of CLABSI may be generalized symptoms or signs of inflammation at the site of insertion.

Patients may present with fever and chills, altered mental status, hypotension, lethargy, or fatigue. Pain, swelling, redness, and discharge may be present at the exit site and along the subcutaneous tract.

**Diagnosis**

- Clinical symptoms of sepsis, like fever, chills, hypotension, apnea, hypothermia, or bradycardia, can be seen in patients with CLABSI.
- Blood cultures are the primary diagnostic modality for CLABSI.

**CDC criteria for the diagnosis of CLABSI are as follows:**

- In a patient who has an eligible central line:
- One or more positive blood culture isolation of an organism not commonly present on the skin

- Two or more positive blood cultures collected on separate occasions when the organism is a skin commensal (the patient has clinical signs of bloodstream infection)

The organisms isolated in both situations must not be related to any other site-specific infection.

Host Factors	Device-related Factors	Procedure-related Factors
Chronic illnesses	Catheter type	Emergent Vs. Elective
Immunocompromised states	Catheter location (femoral > internal jugular > subclavian)	Use of full barrier protection Vs. limited
Malnutrition		Catheter site care
Total parenteral nutrition		The skill of the healthcare worker who inserts the catheter
Elderly		
Neonates		
Burns		

In exit site infections, signs of inflammation are confined to a 2 cm area around the catheter exit site with the presence of culture-positive exudate.

The inflammation extends beyond 2 cm from the exit site and along the subcutaneous track with culture-positive exudate at the exit site in tunnel infections (Figure 5).




Figure 5: Diagnosis of CLABSI

## Management

Empirical therapy must be started in all patients suspected of CLABSI while the blood culture results are awaited. Empirical therapy must not be delayed in these patients and must be most appropriately initiated immediately after drawing the samples for blood culture. Ideally, the hospital antibiogram must guide the choice of empirical therapy. An antibiotic regimen covering

gram-positive and gram-negative organisms may be reasonable in most situations.

**Suggested regimens may be:**

### Gram-positive coverage

- If the high prevalence of MRSA or if MRSA is suspected: Parenteral Vancomycin to cover gram positives
- If the low prevalence of MRSA or if MRSA is not suspected: Nafcillin or Cefazolin may be ideal

**Gram-negative coverage (choice of antibiotics must be determined by the local susceptibility pattern)**

- Beta-lactam/Beta-lactam inhibitor combination
- Cefepime
- Carbapenem ± aminoglycoside

**If infection with *Pseudomonas* is suspected (prior colonization, neutropenia, or debilitation is present)**

- Ceftazidime
- Carbapenems

**If candidemia is suspected (malignancy, transplant recipients, total parenteral nutrition, prolonged broad-spectrum antibiotic coverage, femoral catheterization)**

- Intravenous fluconazole
- Echinocandins if azole resistance is suspected (prior use of azoles or prevalence of *C. glabrata* or *C. krusei*)

## Prevention

Central Line-associated Blood-stream Infection (CLABSI) is one of the most prevalent hospital-acquired infections seen, especially in intensive care units (ICUs). According to APIC, this HAI accounts for approximately ten to twenty-five thousand preventable deaths and eighty-four thousand to two thousand avoidable infections annually.

Earlier, many institutions set goals for eliminating CLABSI, called 'zero CLABSI' or 'targeting zero' programs. Nevertheless, these goals remained challenging to achieve and also to sustain. Hence, recent evidence suggests CLABSI elimination may happen most possibly in ICU patients. One can minimize the rate of CLABSI incidence by following CLABSI prevention bundle strategies in ICUs, hemodialysis patients, and others.

Pediatric patients are more prone to CLABSI due to intrinsic factors such as immature immune systems and birth weight. Frequent and invasive vascular access, either for blood sampling or infusion, patient positioning, and increased hospital stay, are other reasons that increase the risk for CLABSI.

The risk for CLABSI is highest in patients with congenital heart diseases. Neutropenia, total parenteral nutrition, compromised mucosal integrity in patients with oncologic and hematologic diseases may lead to increased risk of CLABSI. The prevention and management of CLABSI in the Neonatal Intensive Care Unit are very challenging. This is because of the increased vulnerability of the patients and the necessity for invasive devices.


Bathing and oral care might minimize the risk of CLABSI. Skin disinfection can help in preventing CLABSI. However, the selection of disinfectant is crucial both for infection prevention and to preserve the integrity of the skin of pediatric patients.

#### Prior to insertion of a Central Line:

- All healthcare professionals involved in the insertion of a central line must be educated and trained, and periodically assessed in all procedures involved in the insertion and maintenance of a central line.
- Only trained personnel should be designated for the insertion and maintenance of a central line.
- An optimal nurse to patient ratio must be maintained in ICUs.

#### During insertion of a Central Line:

- The risks and benefits of insertion of a central line must be considered before insertion to reduce infections.
- A subclavian line must be preferred over a jugular or a femoral site in adult patients when a non-tunneled CVC is placed. A femoral vein must be avoided as much as possible. However, a subclavian line must be avoided in patients with renal disease. Instead, a fistula or graft must be preferred.
  - The appropriate central venous catheter, with the minimum number of ports or lumens, must be chosen.
  - Ultrasound-guided insertion done by experienced personnel can reduce the number of attempts and mechanical complications.
  - Before performing the procedure, scrub your hands with soap and water or an alcohol-based rub. Hand hygiene is the key! Hand hygiene must be performed before and after palpation of the insertion sites and before and after insertion, dressing, accessing, or any other form of manipulation of the central line.
  - Perform the procedure using the aseptic technique. Appropriate barrier precautions including a sterile mask, gown, gloves, cap, and a drape while inserting the central line.
  - Skin antisepsis has to be done with chlorhexidine gluconate and alcohol before inserting a central line.



- Emergency catheterizations can have an increased risk of CLABSI. In case of emergency insertion where implementation of asepsis cannot be assured, the central line must be replaced within 48 hours.

#### Prevention during catheter maintenance:

- Remember, hand hygiene is the key. Scrub your hands before manipulating or removal of catheters.
- Strict aseptic conditions have to be maintained during maintenance and care of the central line.
- The site has to be covered with sterile gauze or semi-permeable dressings
- Semi-permeable dressings must be replaced every seven days, while gauze dressings must be replaced every two days. Also, if the dressing is soiled or dampened, replace it.
- Assess the need for the line daily and remove it promptly when not required.

#### CLABSI Prevention Bundle

- The strategies that form the cornerstone of the prevention of CLABSI constitute the CLABSI




Figure 6: CLABI Prevention Bundle

bundle. These include (Figure 6):

- Hand hygiene
- Use of barrier precautions during insertion
- Selection of appropriate site (In adult patients, avoid femoral vein)
- Antisepsis of skin with alcohol-based chlorhexidine
- Disinfection of the catheter hub for each access
- Review of the position of a central line periodically
- Removal of unnecessary central lines promptly

## Summary (Figure 7)



Figure 7: Summary of CLABSI

## Competing Interests

AA was supported by the National Research University Project of the Thailand Office of Higher Education Commission. The authors declare that they have no competing interests.

## Authors' Contributions

LML drafted the manuscript and AA did the initial editing before revised manuscript was seen by other authors for further comments. All authors read and approved the final manuscript.

## References

- Haddadin Y, Annamaraju P, Regunath H. Central Line Associated Blood Stream Infections. [Updated 2020 Dec 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK430891/>
- Ling, M. L., Apisarnthanarak, A., Jaggi, N., Harrington, G., Morikane, K., Thu, L. T. A., ... Lee, C.-M. (2016). APSIC guide for prevention of Central Line Associated Bloodstream Infections (CLABSI). *Antimicrobial Resistance and Infection Control*, 5, 16.
- O'Grady, N. P., Alexander, M., Burns, L. A., Dellinger, E. P., Garland, J., Heard, S. O., ... the Healthcare Infection Control Practices Advisory Committee (HICPAC) (Appendix 1). (2011). Guidelines for the Prevention of Intravascular Catheter-related Infections. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, 52(9), e162–e193.
- The Joint Commission. Preventing Central Line–Associated Bloodstream Infections: A Global Challenge, a Global Perspective. Oak Brook: Joint Commission Resources; 2012.
- Pronovost P, Needham D, Berenholtz S, Frank J, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. *N Engl J Med*. 2006;355(26):2725–32.
- Datta P, Rani H, Chauhan R, Gombar S, Chander J. Health-care-associated infections: Risk factors and epidemiology from an intensive care unit in Northern India. *Indian J Anaesth*. 2014;58(1):30–5.
- Fraenkel D, Rickard C, Thomas P, Faoagali J, George N, Ware R. A prospective, randomized trial of rifampicin-minocycline-coated and silver-platinum-carbon-impregnated central venous catheters. *Crit Care Med*. 2006;34(3):668–75.
- Kim SH, Song KI, Chang JW, Kim SB, Sung SA, Jo SK, et al. Prevention of uncuffed hemodialysis catheter-related bacteremia using an antibiotic lock technique: a prospective, randomized clinical trial. *Kidney Int*. 2006;69(1):161–4.
- Richards B, Chaboyer W, Bladen T, Schluter PJ. Effect of central venous catheter type on infections: a prospective clinical trial. *J Hosp Infect*. 2003;54(1):10–7.
- Sheng WH, Ko WJ, Wang JT, Chang SC, Hsueh PR, Luh KT. Evaluation of antiseptic-impregnated central venous catheters for prevention of catheter-related infection in

- intensive care unit patients. *Diagn Microbiol Infect Dis.* 2000;38(1):1–5.
11. Yoshida J, Ishimaru T, Fujimoto M, Hirata N, Matsubara N, Koyanagi N. Risk factors for central venous catheter-related bloodstream infection: a 1073-patient study. *J Infect Chemother.* 2008;14(6):399–403.
  12. Zhang P, Yuan J, Tan H, Lv R, Chen J. Successful prevention of cuffed hemodialysis catheter-related infection using an antibiotic lock technique by strictly catheter-restricted antibiotic lock solution method. *Blood Purif.* 2009;27(2):206–11.
  13. Apisarnthanarak A, Greene MT, Kennedy EH, Khawcharoenporn T, Krein S, Saint S. National survey of practices to prevent healthcare-associated infections in Thailand: the role of safety culture and collaboratives. *Infect Control Hosp Epidemiol.* 2012;33(7):711–7. doi:10.1086/666330. Epub 2012 May 14.
  14. Apisarnthanarak A, Khawcharoenporn T, Mundy LM. National survey of suboptimal and unnecessary practices for central line placement and management in Thailand. *Am J Infect Control.* 2013;41(2):e11–3. doi:10.1016/j.ajic.2012.07.019.
  15. Jaggi N, Sissodia P. Repeated multimodal supervision programs to reduce the central line-associated bloodstream infection rates in an Indian corporate hospital. *Healthcare Infection.* 2014;19:53–8. <http://dx.doi.org/10.1071/HI13030>.
  16. Jaggi N, Rodrigues C, Rosenthal VD, Todi SK, Shah S, Saini N, et al. Impact of an International Nosocomial Infection Control Consortium multidimensional approach on central line-associated bloodstream infection rates in adult intensive care units in eight cities in India. *Int J Infect Dis.* 2013;17(12):1218–24.
  17. Jaggi N, Nirwan P, Naryana E, Kaur KP. The analysis and impact of three successive intervention programmes directed to reduce central line associated blood stream infections over a four year period in a tertiary care hospital in India. *Antimicrobial Resistance and Infection Control.* 2013;2 Suppl 1:2. doi:10.1186/2047-2994-2-S1-P2.
  18. Parienti J, Mongardon N, Megarbane B, Mira J, Kalfon P, Gros A, et al. Intravascular complications of central venous catheterization by insertion site. *N Engl J Med.* 2015;373:1220–9. doi:10.1056/NEJMoa1500964.
  19. Parienti JJ, Thirion M, Megarbane B, et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. *JAMA.* 2008;299:2413–22.
  20. Nagashima G, Kikuchi T, Tsuyuzaki H, et al. To reduce catheter-related bloodstream infections: is the subclavian route better than the jugular route for central venous catheterization? *J Infect Chemother.* 2006;12:363–5.
  21. Hind D, Calvert N, McWilliams R, et al. Ultrasonic locating devices for central venous cannulation: meta-analysis. *BMJ.* 2003;327:361.
  22. Larson EL, Rackoff WR, Weiman M, et al. APIC guideline for handwashing and hand antisepsis in health care settings. *Am J Infect Control.* 1995;23:251–69.
  23. WHO Guidelines on Hand Hygiene in Health Care: a Summary 2009.
  24. Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. *Lancet.* 1991;338:339–43.
  25. Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. *Ann Intern Med.* 2002;136:792–801.
  26. Raad II, Hohn DC, Gilbreath BJ, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. *Infect Control Hosp Epidemiol.* 1994;15:231–8.
  27. Lin TY, Lee CM, Wang FD, et al. Taiwan guidelines for prevention and control of intravascular catheter-related bloodstream infections. 2011.
  28. O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. *Clin Infect Dis.* 2011;52(9):e162-93. doi:10.1093/cid/cir257.
  29. Guidelines for the Prevention of Intravascular Catheter-Related Infections, CDC 2011 (available at: <http://www.cdc.gov/hicpac/pdf/guidelines/bsi-guidelines-2011.pdf>)
  30. Guide to the eliminations of catheter-related bloodstream infections- An APIC guide 2009.
  31. Getting Started Kit: Prevent Central Line Infections, Central Line Associated - Blood Stream Infections (CLA-BSI) Safer Healthcare Now! Campaign (SHN) 2009
  32. Central line insertion and maintenance guidelines. Australian Commission on Safety and Quality in Health care 2012.
  33. Camp-Sorrell D, editor. Access Device Guidelines: Recommendations for Nursing Practice and Education. 3rd ed. Pittsburgh: Oncology Nursing Society; 2011. Copyright 2011 by ONS. INS 2011 Infusion Nursing Standards of Practice.
  34. Basic Infection Control And Prevention Plan for Outpatient Oncology Settings CDC December 2011
  35. Guide to the Elimination of Infections in Hemodialysis, An APIC Guide 2010
  36. NHMRC Australian Guidelines for the Prevention and Control of Infection in Healthcare. Commonwealth of Australia 2010.
  37. JCI. 2012. Preventing Central Line-Associated Bloodstream Infections. A Global Challenge, A Global Perspective. Available from: [www.jointcommission.org/assets/1/18/clabsi\\_monograph.pdf](http://www.jointcommission.org/assets/1/18/clabsi_monograph.pdf)
  38. CDC. 2011 Guidelines for the Prevention of Intravascular Catheter-Related Infections. Available from: <http://www.cdc.gov/hicpac/pdf/guidelines/bsi-guidelines-2011.pdf>
  39. Guide H-t. Prevent Central Line-Associated Bloodstream Infections. Cambridge: Institute for Healthcare Improvement; 2012.
  40. Weaver SJ, Lubomksi LH, Wilson RF, Pfoh ER, Martinez KA, Dy SM. Promoting a culture of safety as a patient safety strategy: a systematic review. *Ann Intern Med.* 2013;158(5 pt 2):369–74.
  41. Hatler CW, Mast D, Corderella J, et al. Using evidence and process improvement strategies to enhance healthcare

outcomes for the critically ill: a pilot project. *Am J Crit Care.* 2006;15(6):549–55.

42. Warye KL, Murphy DM. Targeting zero health care-associated infections. *Am J Infect Control.* 2008;36:683–4.

**Submit your manuscript to the World Journal of Case Reports and Clinical Images** and benefit from:

- ✚ Convenient online submission
- ✚ Rigorous peer review
- ✚ Immediate publication on acceptance
- ✚ Open access: articles freely available online
- ✚ High visibility within the field
- ✚ Retaining the copyright to your article

*Submit your manuscript at*  
<https://worldjournalofcasereports.org/>

&  
[wjcasereports@gmail.com](mailto:wjcasereports@gmail.com);  
[submission@worldjournalofcasereports.org](mailto:submission@worldjournalofcasereports.org)

